Skip to main content
Top

05-03-2025 | Melanoma | Original Article

Effects of Age, Gender, Histopathology, and Anatomical Location of the Lesion on BRAF Mutation in Turkish Cutaneous Melanoma Patients

Author: Faruk Tas

Published in: Indian Journal of Surgery

Login to get access

Abstract

Skin melanoma patients with BRAF mutations tend to be more aggressive and have unfavorable survival rates than BRAF wild-type melanomas. We aimed to investigate to effects of age, gender, histopathology, and anatomical location of the lesion on BRAF mutation in Turkish cutaneous melanoma patients in this study. A total of 270 cutaneous melanoma patients with known BRAF mutation status were investigated retrospectively. BRAF mutation was observed in 141 (52.2%) patients and was slightly higher (52.5%) in males compared to females. The frequency of BRAF mutation decreased proportionally with aging — the highest rate in those younger than 35 years of age, the lowest rate in those older than 65 years — the location of the lesion away from the body — highest in the trunk, lowest in the fingers — and having less frequent histopathologies — most frequently in superficial-spreading pathology and lowest in acral lentiginous and lentigo maligna melanoma. In conclusion, we determined that the BRAF mutation frequency in Turkish melanoma patients is equivalent to the Western population average, and that varied significantly with age, histopathology, and location of the lesion.
Literature
1.
go back to reference Castellani G, Buccarelli M, Arasi MB, Rossi S, Pisanu ME, Bellenghi M et al (2023) BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers. Cancers 15:4026CrossRefPubMedPubMedCentral Castellani G, Buccarelli M, Arasi MB, Rossi S, Pisanu ME, Bellenghi M et al (2023) BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers. Cancers 15:4026CrossRefPubMedPubMedCentral
2.
go back to reference Dixon AJ, Sladden M, Zouboulis CC, Popescu CM, Nirenberg A, Steinman HK et al (2024) Primary cutaneous melanoma—management in 2024. J Clin Med 13:1607CrossRefPubMedPubMedCentral Dixon AJ, Sladden M, Zouboulis CC, Popescu CM, Nirenberg A, Steinman HK et al (2024) Primary cutaneous melanoma—management in 2024. J Clin Med 13:1607CrossRefPubMedPubMedCentral
3.
go back to reference Dudin O, Mintser O, Kobyliak N, Kaminskyi D, Shabalkov R, Matvieieva A et al (2023) Incidence of BRAF mutations in cutaneous melanoma: histopathological and molecular analysis of a Ukrainian population. Melanoma Manag 10(1):MMT64CrossRefPubMedPubMedCentral Dudin O, Mintser O, Kobyliak N, Kaminskyi D, Shabalkov R, Matvieieva A et al (2023) Incidence of BRAF mutations in cutaneous melanoma: histopathological and molecular analysis of a Ukrainian population. Melanoma Manag 10(1):MMT64CrossRefPubMedPubMedCentral
4.
go back to reference Neville G, Marzario B, Shilling D, Hand CK, Heffron C (2024) Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma. Virchows Arch 484:475–479CrossRefPubMedPubMedCentral Neville G, Marzario B, Shilling D, Hand CK, Heffron C (2024) Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma. Virchows Arch 484:475–479CrossRefPubMedPubMedCentral
5.
go back to reference Zablocka T, Kreismane M, Pjanova D, Isajevs S (2022) Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma. Oncol Lett 25(1):27CrossRefPubMedPubMedCentral Zablocka T, Kreismane M, Pjanova D, Isajevs S (2022) Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma. Oncol Lett 25(1):27CrossRefPubMedPubMedCentral
6.
7.
go back to reference van der Kooij MK, Dekkers OM, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB et al (2021) Sex-based differences in treatment with immune checkpoint inhibition and targeted therapy for advanced melanoma: a nationwide cohort study. Cancers 13:4639CrossRefPubMedPubMedCentral van der Kooij MK, Dekkers OM, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB et al (2021) Sex-based differences in treatment with immune checkpoint inhibition and targeted therapy for advanced melanoma: a nationwide cohort study. Cancers 13:4639CrossRefPubMedPubMedCentral
8.
go back to reference Colombino M, Rozzo C, Paliogiannis P, Casula M, Manca A, Doneddu V (2020) Comparison of BRAF mutation screening strategies in a large real-life series of advanced melanoma patients. J Clin Med 9:2430CrossRefPubMedPubMedCentral Colombino M, Rozzo C, Paliogiannis P, Casula M, Manca A, Doneddu V (2020) Comparison of BRAF mutation screening strategies in a large real-life series of advanced melanoma patients. J Clin Med 9:2430CrossRefPubMedPubMedCentral
9.
go back to reference Lokhandwala PM, Tseng LH, Rodriguez E, Zheng G, Pallavajjalla A, Gocke CD et al (2019) Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. BMC Cancer 19:665CrossRefPubMedPubMedCentral Lokhandwala PM, Tseng LH, Rodriguez E, Zheng G, Pallavajjalla A, Gocke CD et al (2019) Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. BMC Cancer 19:665CrossRefPubMedPubMedCentral
10.
go back to reference Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239–1246CrossRefPubMed Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239–1246CrossRefPubMed
11.
go back to reference Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R et al (2007) Distinct clinical and pathological features are associated with the BRAFT1799A(V600E) mutation in primary melanoma. J Invest Dermatol 127:900–905CrossRefPubMed Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R et al (2007) Distinct clinical and pathological features are associated with the BRAFT1799A(V600E) mutation in primary melanoma. J Invest Dermatol 127:900–905CrossRefPubMed
Metadata
Title
Effects of Age, Gender, Histopathology, and Anatomical Location of the Lesion on BRAF Mutation in Turkish Cutaneous Melanoma Patients
Author
Faruk Tas
Publication date
05-03-2025
Publisher
Springer India
Published in
Indian Journal of Surgery
Print ISSN: 0972-2068
Electronic ISSN: 0973-9793
DOI
https://doi.org/10.1007/s12262-025-04331-x
SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now
Video